

## Overview

### Useful For

Confirming a diagnosis of X-linked adrenoleukodystrophy

Identifying a variant in the *ABCD1* gene

### Reflex Tests

| Test Id | Reporting Name                      | Available Separately | Always Performed |
|---------|-------------------------------------|----------------------|------------------|
| CULFB   | Fibroblast Culture for Genetic Test | Yes                  | No               |

### Genetics Test Information

Testing includes full gene sequencing of the *ABCD1* gene.

### Testing Algorithm

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

For more information see

[-Newborn Screen Follow-up for X-Linked Adrenoleukodystrophy](#)

[-Newborn Screening Act Sheet X-linked Adrenoleukodystrophy: Increased Very Long Chain Fatty Acids](#)

### Special Instructions

- [Molecular Genetics: Biochemical Disorders Patient Information](#)
- [Informed Consent for Genetic Testing](#)
- [Blood Spot Collection Card-Spanish Instructions](#)
- [Newborn Screening Act Sheet X-linked Adrenoleukodystrophy: Increased Very Long Chain Fatty Acids](#)
- [Newborn Screen Follow-up for X-Linked Adrenoleukodystrophy](#)
- [Blood Spot Collection Card-Chinese Instructions](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Blood Spot Collection Instructions](#)

### Method Name

Polymerase Chain Reaction (PCR) followed by DNA Sequencing

### NY State Available

Yes

## Specimen

**Specimen Type**

Varies

**Ordering Guidance**

The preferred first-tier screening test for X-linked adrenoleukodystrophy is POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum.

**Shipping Instructions**

Specimen preferred to arrive within 96 hours of collection.

**Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

**Submit only 1 of the following specimens:****Preferred:****Specimen Type:** Whole blood**Container/Tube:****Preferred:** Lavender top (EDTA) or yellow top (ACD)**Acceptable:** Any anticoagulant**Specimen Volume:** 3 mL**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

**Specimen Stability Information:** Ambient (preferred)/Refrigerated**Specimen Type:** Cultured fibroblasts**Container/Tube:** T-75 or T-25 flask**Specimen Volume:** 1 Full T-75 flask or 2 full T-25 flasks**Specimen Stability Information:** Ambient (preferred)/Refrigerated <24 hours**Additional Information:** A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.**Supplies:** Fibroblast Biopsy Transport Media (T115)**Specimen Type:** Skin biopsy**Container/Tube:** Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.).**Specimen Volume:** 4-mm punch**Specimen Stability Information:** Refrigerated (preferred)/Ambient**Additional Information:** A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.

**Specimen Type:** Blood spot

**Supplies:** Card - Blood Spot Collection (Filter Paper) (T493)

**Container/Tube:**

**Preferred:** Collection card (Whatman Protein Saver 903 Paper)

**Acceptable:** PerkinElmer 226 (formerly Ahlstrom 226) filter paper, or blood spot collection card

**Specimen Volume:** 2 to 5 Blood spots

**Collection Instructions:**

1. An alternative blood collection option for a patient older than 1 year is a fingerstick. For detailed instructions, see [How to Collect Dried Blood Spot Samples](#).
2. Let blood dry on the filter paper at ambient temperature in a horizontal position for a minimum of 3 hours.
3. Do not expose specimen to heat or direct sunlight.
4. Do not stack wet specimens.
5. Keep specimen dry.

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Additional Information:**

1. Due to lower concentration of DNA yielded from blood spot, it is possible that additional specimen may be required to complete testing.
2. For collection instructions, see [Blood Spot Collection Instructions](#).
3. For collection instructions in Spanish, see [Blood Spot Collection Card-Spanish Instructions](#) (T777).
4. For collection instructions in Chinese, see [Blood Spot Collection Card-Chinese Instructions](#) (T800).

## Forms

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:

-[Informed Consent for Genetic Testing](#) (T576)

-[Informed Consent for Genetic Testing-Spanish](#) (T826)

2. [Molecular Genetics: Biochemical Disorders Patient Information](#) (T527)

3. If not ordering electronically, complete, print, and send a [Biochemical Genetics Test Request](#) (T798) with the specimen.

## Specimen Minimum Volume

Blood: 1 mL

Blood Spots: 5 punches-3 mm diameter

## Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

## Specimen Stability Information

| Specimen Type | Temperature | Time | Special Container |
|---------------|-------------|------|-------------------|
| Varies        | Varies      |      |                   |

## Clinical & Interpretive

---

**Clinical Information**

X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disease characterized by magnetic resonance imaging (MRI) findings in the white matter, adrenocortical insufficiency, and abnormal plasma concentrations of very long chain fatty acids. The phenotypic expression of X-ALD varies widely. The phenotypes can be subdivided into 3 main categories: childhood cerebral form, adrenomyeloneuropathy (AMN), and Addison disease only. The childhood cerebral form has onset of symptoms between ages 4 and 8, beginning with attention deficit hyperactivity disorder-like symptoms with progressive cognitive, behavior, vision, hearing, and motor deterioration. AMN usually presents in males in their late twenties as progressive paraparesis, sexual dysfunction, sphincter disturbances, and abnormalities in adrenocortical function. The Addison only phenotype typically presents by age 7.5 with adrenocortical insufficiency without significant neurological involvement. Most of these patients eventually develop AMN. Some female carriers may experience mild AMN symptoms with a later age of onset.

The phenotype cannot be predicted by very long chain fatty acids (VLCFA) plasma concentration or by the nature of the genetic variant. The same variant can be associated with each of the known phenotypes. Different phenotypes often occur within a family.

POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum testing is the preferred first-tier screening method for X-ALD. This is abnormal in 99% of affected males and 85% of carrier females. Sequencing of the *ABCD1* gene is available to confirm the diagnosis of X-ALD, improve carrier detection, and assist with prenatal diagnosis.

**Reference Values**

An interpretive report will be provided.

**Interpretation**

All detected alterations are evaluated according to American College of Medical Genetics and Genomics recommendations.<sup>(1)</sup> Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

**Cautions**

A small percentage of individuals who have a diagnosis of X-linked adrenoleukodystrophy (X-ALD) may have a variant that is not identified by this method (eg, large deletions/duplications, promoter alterations, deep intronic alterations). The absence of variants, therefore, does not eliminate the possibility of the diagnosis of X-ALD. For testing asymptomatic individuals it is important to first document the presence of an *ABCD1* gene variant in an affected family member.

In some cases, DNA alterations of undetermined significance may be identified.

Rare alterations exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in our interpretation of results may occur if information given is inaccurate or incomplete.

**Clinical Reference**

1. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus

---

recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424

2. Moser HW, Mahmood A, Raymond GV: X-linked adrenoleukodystrophy. Nat Clin Pract Neurol. 2007 Mar;3(3):140-151

3. Wang Y, Busin R, Reeves C, et al: X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism. Mol Genet Metab. 2011 Sep-Oct;104(1-2):160-166

4. Kemp S, Berger J, Aubourg P: X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012 Sept;1822(9):1465-1474

## Performance

### Method Description

Bidirectional sequence analysis is performed to test for the presence of a variant in all coding regions and intron/exon boundaries of the *ABCD1* gene.(Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Varies

### Report Available

14 to 20 days

### Specimen Retention Time

Whole Blood: 2 weeks (if available); Extracted DNA: 3 months

### Performing Laboratory Location

Rochester

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### CPT Code Information

81405-*ABCD1* (ATP-binding cassette, sub-family D [ALD] member 1) (eg, adrenoleukodystrophy) full gene sequence  
 88233-Tissue culture, skin or solid tissue biopsy (if appropriate)  
 88240-Cryopreservation (if appropriate)

**LOINC® Information**

| Test ID | Test Order Name           | Order LOINC® Value |
|---------|---------------------------|--------------------|
| XALDZ   | X-ALD, Full Gene Analysis | 95782-9            |

| Result ID | Test Result Name       | Result LOINC® Value |
|-----------|------------------------|---------------------|
| 53561     | Result Summary         | 50397-9             |
| 53562     | Result                 | 82939-0             |
| 53563     | Interpretation         | 69047-9             |
| 53564     | Additional Information | 48767-8             |
| 53565     | Specimen               | 31208-2             |
| 53566     | Source                 | 31208-2             |
| 53567     | Released By            | 18771-6             |